Rabbit Recombinant Monoclonal YB1 antibody - conjugated to HRP.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation (PubMed:10817758, PubMed:11698476, PubMed:14718551, PubMed:18809583, PubMed:31358969, PubMed:8188694). Predominantly acts as a RNA-binding protein: binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C) (PubMed:19561594, PubMed:31358969). Promotes mRNA stabilization: acts by binding to m5C-containing mRNAs and recruiting the mRNA stability maintainer ELAVL1, thereby preventing mRNA decay (PubMed:10817758, PubMed:11698476, PubMed:31358969). Component of the CRD-mediated complex that promotes MYC mRNA stability (PubMed:19029303). Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors (By similarity). Plays a key role in RNA composition of extracellular exosomes by defining the sorting of small non-coding RNAs, such as tRNAs, Y RNAs, Vault RNAs and miRNAs (PubMed:27559612, PubMed:29073095). Probably sorts RNAs in exosomes by recognizing and binding C5-methylcytosine (m5C)-containing RNAs (PubMed:28341602, PubMed:29073095). Acts as a key effector of epidermal progenitors by preventing epidermal progenitor senescence: acts by regulating the translation of a senescence-associated subset of cytokine mRNAs, possibly by binding to m5C-containing mRNAs (PubMed:29712925). Also involved in pre-mRNA alternative splicing regulation: binds to splice sites in pre-mRNA and regulates splice site selection (PubMed:12604611). Binds to TSC22D1 transcripts, thereby inhibiting their translation and negatively regulating TGF-beta-mediated transcription of COL1A2 (By similarity). Also able to bind DNA: regulates transcription of the multidrug resistance gene MDR1 is enhanced in presence of the APEX1 acetylated form at 'Lys-6' and 'Lys-7' (PubMed:18809583). Binds to promoters that contain a Y-box (5'-CTGATTGGCCAA-3'), such as MDR1 and HLA class II genes (PubMed:18809583, PubMed:8188694). Promotes separation of DNA strands that contain mismatches or are modified by cisplatin (PubMed:14718551). Has endonucleolytic activity and can introduce nicks or breaks into double-stranded DNA, suggesting a role in DNA repair (PubMed:14718551). The secreted form acts as an extracellular mitogen and stimulates cell migration and proliferation (PubMed:19483673).
NSEP1, YB1, YBX1, Y-box-binding protein 1, YB-1, CCAAT-binding transcription factor I subunit A, DNA-binding protein B, Enhancer factor I subunit A, Nuclease-sensitive element-binding protein 1, Y-box transcription factor, CBF-A, DBPB, EFI-A
Rabbit Recombinant Monoclonal YB1 antibody - conjugated to HRP.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Not recommended for mouse IHC.
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Y-box Binding Protein 1 (YB1) also known as YBX1 is a multifunctional protein with a mass of approximately 36 kDa. It belongs to the cold shock protein family that contains a highly conserved cold shock domain. YB1 is broadly expressed across many tissues predominantly found in the cytoplasm and nucleus where it functions as a transcription factor and RNA-binding protein. Through its transcriptional regulatory activity YB1 can bind to Y-box sequences in the promoter regions of genes and modulate their expression.
YB1 plays vital roles in regulating cell proliferation stress response and differentiation. It does not operate alone; it interacts with various complexes notably ribonucleoprotein complexes. YB1 regulates gene expression at both transcriptional and translational levels impacting cell cycle progression and apoptosis pathways. Its ability to bind RNA and DNA makes it integral in controlling the expression of genes related to stress responses and developmental processes.
YB1 is essential in many signaling pathways that govern cell growth and survival including the PI3K/AKT pathway and MAPK pathway. In these pathways it interacts with proteins like AKT1 and MAPK3 influencing cellular responses to external and internal stimuli. These interactions reveal the adaptability of YB1 in various cellular contexts allowing it to mediate pathway-specific responses to environmental cues thereby promoting the maintenance of cellular homeostasis and adaptation.
The dysregulation of YB1 has been linked to cancer and neurodegenerative diseases. Overexpression or altered localization of YB1 often in connection with other proteins such as p53 contributes to tumorigenesis by enhancing cell proliferation and inhibiting programmed cell death. In neurodegenerative diseases impaired YB1 function can negatively affect neuronal survival potentially mediated through its interactions with proteins like tau which are implicated in conditions such as Alzheimer's disease. Understanding of these associations highlights the potential of YB1 as a therapeutic target in disease management.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com